High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial

Susanne Macher, Camilla Drexler, Ines Lindenau, Nazanin Sareban, Peter Schlenke, Karin Amrein, Susanne Macher, Camilla Drexler, Ines Lindenau, Nazanin Sareban, Peter Schlenke, Karin Amrein

Abstract

Background: About 2-3 % of the population participates in blood donation programmes. Each whole blood donation or ten apheresis donations cause a loss of 200-250 mg of iron. As a result, one of the most common risks of regular blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves and higher daily requirements. Besides anaemia, iron deficiency may lead to fatigue and impaired cognitive and physical performance. Current iron preparations for intravenous administration are well tolerated and allow for application of large doses up to 1 g in one visit. Our hypothesis is that in blood donors with iron deficiency, intravenously administered iron is more efficient and as safe as oral iron supplementation. Since anaemia is one of the most frequent reasons for permanent or intermittent donor deferral, maintaining an iron-replete donor pool may help to prevent shortages in blood supply and to avoid iron deficiency-related comorbidities.

Methods/design: In this randomised clinical trial we include male and female blood donors aged ≥18 and ≤65 years with a ferritin value of ≤30 ng/ml. Stratified by gender, participants are randomized with a web-based randomisation tool in a 1:1 ratio to either 1 g of intravenously administered ferric carboxymaltose or 10 g of iron fumarate supplements at one to two daily doses of 100 mg each. Eight to 12 weeks after the first visit, iron status, blood count and symptoms are assessed in both groups. The primary endpoint is the difference in transferrin saturation (%) following the intervention between both groups. Secondary endpoints include other parameters of iron metabolism and red blood cell count, the number of patients with drug-related adverse events, and subjective symptoms including those of the restless legs syndrome, quality of life, and fatigue.

Discussion: Iron supplementation administered intravenously in non-anaemic but iron-deficient blood donors could represent an effective strategy to protect blood donors from comorbidities related with iron deficiency and therefore improve blood donor wellbeing. Furthermore, iron supplementation will help to maintain an iron-replete blood donor pool.

Trial registration: EudraCT: 2013-000327-14, Clinical Trials Identifier: NCT01787526 . Registered on 6 February 2013.

Keywords: Blood donation; Donor safety; Intravenous iron; Iron carboxymaltose; Iron deficiency; Randomised controlled trial.

Figures

Fig. 1
Fig. 1
Study flow chart

References

    1. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–95. doi: 10.1056/NEJM199912233412607.
    1. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585–94. doi: 10.3945/ajcn.114.103366.
    1. Conrad ME, Crosby WH, Jacobs A, Kaltwasser JP, Nusbacher J. The Hippocratian principle of ‘primum nil nocere’ demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma. How much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency? Vox Sang. 1981;41(5–6):336–43.
    1. Semmelrock MJ, Raggam RB, Amrein K, Avian A, Schallmoser K, Lanzer G, et al. Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors. Clin Chim Acta. 2012;413(7–8):678–82. doi: 10.1016/j.cca.2011.12.006.
    1. Simon TL. Iron, iron everywhere but not enough to donate. Transfusion. 2002;42(6):664. doi: 10.1046/j.1537-2995.2002.00121.x.
    1. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. JAMA. 1981;245(20):2038–43. doi: 10.1001/jama.1981.03310450030018.
    1. Brittenham GM. Iron deficiency in whole blood donors. Transfusion. 2011;51(3):458–61. doi: 10.1111/j.1537-2995.2011.03062.x.
    1. Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 2011;51(3):511–22. doi: 10.1111/j.1537-2995.2010.02865.x.
    1. Finch CA, Cook JD, Labbe RF, Culala M. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood. 1977;50(3):441–7.
    1. Baart AM, van Noord PA, Vergouwe Y, Moons KG, Swinkels DW, Wiegerinck ET, et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion. 2013;53(8):1670–7. doi: 10.1111/j.1537-2995.2012.03956.x.
    1. Amrein K, Valentin A, Lanzer G, Drexler C. Adverse events and safety issues in blood donation—a comprehensive review. Blood Rev. 2012;26(1):33–42. doi: 10.1016/j.blre.2011.09.003.
    1. Bundesministerium für Arbeit GuS. BGBl. II Nr. 100/1999 in der geltenden Fassung. 1999.
    1. Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, et al. Oral iron supplementation after blood donation: a randomized clinical trial. JAMA. 2015;313(6):575–83. doi: 10.1001/jama.2015.119.
    1. Bast G, Peisker H, Schumann HD. Latent disorders caused by iron deficiency in frequent blood donors. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1956;283(3):280–90.
    1. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326(7399):1124. doi: 10.1136/bmj.326.7399.1124.
    1. Birgegard G, Schneider K, Ulfberg J. High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sang. 2010;99(4):354–61. doi: 10.1111/j.1423-0410.2010.01368.x.
    1. Pittori C, Buser A, Gasser UE, Sigle J, Job S, Ruesch M, et al. A pilot iron substitution programme in female blood donors with iron deficiency without anaemia. Vox Sang. 2011;100(3):303–11. doi: 10.1111/j.1423-0410.2010.01427.x.
    1. Radtke H, Mayer B, Rocker L, Salama A, Kiesewetter H. Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion. 2004;44(10):1463–7. doi: 10.1111/j.1537-2995.2004.04045.x.
    1. Radtke H, Tegtmeier J, Rocker L, Salama A, Kiesewetter H. Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion. 2004;44(10):1427–32. doi: 10.1111/j.1537-2995.2004.04074.x.
    1. Radtke H, Tegtmeier J, Rocker L, Salama A, Kiesewetter H. Compensating for iron loss in regular blood donors using ferrous gluconate and ascorbic acid. Transfusion. 2005;45(7):1236–7. doi: 10.1111/j.1537-2995.2005.00183.x.
    1. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med. 2012;10:8. doi: 10.1186/1741-7015-10-8.
    1. Bryant BJ, Yau YY, Arceo SM, Daniel-Johnson J, Hopkins JA, Leitman SF. Iron replacement therapy in the routine management of blood donors. Transfusion. 2012;52(7):1566–75. doi: 10.1111/j.1537-2995.2011.03488.x.
    1. Magnussen K, Bork N, Asmussen L. The effect of a standardized protocol for iron supplementation to blood donors low in hemoglobin concentration. Transfusion. 2008;48(4):749–54. doi: 10.1111/j.1537-2995.2007.01601.x.
    1. Magnussen K, Ladelund S. Handling low hemoglobin and iron deficiency in a blood donor population: 2 years’ experience. Transfusion. 2015;55(10):2473–8. doi: 10.1111/trf.13152.
    1. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4. doi: 10.1186/1471-2326-11-4.
    1. Fontana S, Jüni P, Niederhauser C, Keller P. Lack of effectiveness of intravenous iron infusion in healthy blood donors with low ferritin: a double-blind randomized controlled trial. Vox Sang. 2014;107(Supplement S1, Abstracts of the 33rd International Congress of the International Society of Blood Transfusion, Seoul, Korea, May 31–June 5, 2014):98.
    1. Ekermo B, Forsberg P, Schedvin G. An open, randomised, clinical study of oral versus intravenous iron for iron substitution in blood donors. Transfusion. 2013;53(Supplement: Abstract Presentations from the AABB Annual Meeting and CTTXPO, Denver, CO, October 12–15, 2013):36A.
    1. Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials. Clin Drug Investig. 2016;36(3):177–94. doi: 10.1007/s40261-015-0361-z.
    1. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314(19):2062–8. doi: 10.1001/jama.2015.15572.
    1. Gravesen E, Hofman-Bang J, Mace ML, Lewin E, Olgaard K. High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol. 2013;14:281. doi: 10.1186/1471-2369-14-281.
    1. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675. doi: 10.1155/2015/468675.
    1. Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature. Case Rep Endocrinol. 2014;2014:843689.
    1. Sangros SMJ, Goni GE, Camarero SA, Estebanez EC, Lozano MME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016. doi: 10.1016/j.remn.2016.04.006.
    1. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435. doi: 10.1016/j.ajog.2008.07.046.
    1. Bani M, Giussani B. Gender differences in giving blood: a review of the literature. Blood Transfus. 2010;8(4):278–87.
    1. Bianco C, Brittenham G, Gilcher RO, Gordeuk VR, Kushner JP, Sayers M, et al. Maintaining iron balance in women blood donors of childbearing age: summary of a workshop. Transfusion. 2002;42(6):798–805. doi: 10.1046/j.1537-2995.2002.00103.x.
    1. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion. 2006;46(10):1667–81. doi: 10.1111/j.1537-2995.2006.00969.x.
    1. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood. 1986;68(3):726–31.
    1. Skikne B, Lynch S, Borek D, Cook J. Iron and blood donation. Clin Haematol. 1984;13(1):271–87.
    1. Scholl TO, Hediger ML. Anemia and iron-deficiency anemia: compilation of data on pregnancy outcome. Am J Clin Nutr. 1994;59(2 Suppl):492S–500.
    1. Pollitt E. Iron deficiency and cognitive function. Annu Rev Nutr. 1993;13:521–37. doi: 10.1146/annurev.nu.13.070193.002513.
    1. Carter RC, Jacobson JL, Burden MJ, Armony-Sivan R, Dodge NC, Angelilli ML, et al. Iron deficiency anemia and cognitive function in infancy. Pediatrics. 2010;126(2):e427–34. doi: 10.1542/peds.2009-2097.
    1. Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci. 1992;50(26):2059–65. doi: 10.1016/0024-3205(92)90572-7.
    1. Ackrell BA, Maguire JJ, Dallman PR, Kearney EB. Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem. 1984;259(16):10053–9.
    1. Ward RJ, Crichton RR, Taylor DL, Della Corte L, Srai SK, Dexter DT. Iron and the immune system. J Neural Transm (Vienna, Austria: 1996) 2011;118(3):315–28. doi: 10.1007/s00702-010-0479-3.
    1. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348(9033):992–6. doi: 10.1016/S0140-6736(96)02341-0.
    1. Ulfberg J, Nystrom B. Restless legs syndrome in blood donors. Sleep Med. 2004;5(2):115–8. doi: 10.1016/j.sleep.2003.09.010.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera